vtv
therapeutics
presents
additional
positive
clinical
study
results
supporting
safety
efficacy
adjunctive
therapy
patients
type
diabetes
high
point
globe
newswire
vtv
therapeutics
nasdaq
vtvt
yesterday
presented
data
completed
phase
study
support
clinical
potential
oral
adjunctive
therapy
type
diabetes
newly
reported
data
provide
additional
evidence
suggesting
increase
risk
diabetic
ketoacidosis
dka
serious
potentially
complication
occurs
patients
due
unique
mechanism
action
dka
known
shortcoming
several
investigational
oral
therapies
advanced
positive
impact
ketone
levels
point
important
differentiation
company
also
presented
additional
data
study
confirming
treatment
resulted
significant
improvements
reduction
bolus
insulin
dose
without
increasing
risk
hypoglycemia
dka
data
presented
easd
add
growing
body
evidence
supporting
potential
meet
urgent
yet
still
unmet
need
adjunctive
therapy
patients
living
improves
disease
management
health
outcomes
said
steve
holcombe
president
ceo
vtv
therapeutics
development
adjunctive
oral
therapies
limited
unacceptable
rates
hypoglycemia
ketoacidosis
absence
events
study
important
advance
vtv
therapeutics
research
community
whole
body
evidence
provides
robust
foundation
initiate
first
pivotal
study
expect
commence
end
data
presented
two
oral
presentations
annual
meeting
european
association
study
diabetes
held
virtually
september
available
download
https
pipeline
people
dependent
insulin
survival
yet
unable
achieve
recommended
glycemic
targets
avoid
complications
current
insulin
regimens
said
esther
latres
assistant
vice
president
research
jdrf
provided
funding
support
study
adjunctive
therapy
could
enhance
glucose
control
reduce
need
insulin
improve
health
outcomes
would
transform
lives
individuals
living
believe
data
support
continued
development
oral
adjunctive
therapy
population
look
forward
seeing
results
planned
pivotal
easd
virtual
presentation
information
oral
presentation
title
trial
activation
glucokinase
improves
glycaemic
control
patients
type
diabetes
presentation
number
category
op
novel
agents
type
diabetes
date
time
tuesday
september
et
oral
presentation
title
mechanism
matter
preliminary
evidence
activation
glucokinase
increase
plasma
urine
ketones
type
diabetes
presentation
number
category
op
novel
agents
type
diabetes
date
time
tuesday
september
et
study
randomized
adaptive
study
assessing
safety
efficacy
adjunct
insulin
therapy
adults
primary
endpoint
change
week
study
conducted
support
jdrf
leading
global
organization
funding
research
type
diabetes
phase
study
conducted
two
parts
protocol
evaluate
safety
efficacy
patients
weeks
daily
dosing
following
insulin
optimization
placebo
period
part
enrolled
patients
insulin
pumps
cgms
positive
topline
results
learning
phase
part
reported
june
confirming
phase
part
enrolled
patients
used
either
insulin
pumps
multiple
daily
injections
insulin
cgms
allowed
patients
using
devices
least
three
months
prior
start
study
type
diabetes
type
diabetes
autoimmune
disease
person
pancreas
stops
producing
insulin
hormone
enables
people
get
energy
food
occurs
body
immune
system
attacks
destroys
cells
pancreas
called
beta
cells
causes
yet
entirely
understood
scientists
believe
genetic
factors
environmental
triggers
involved
onset
nothing
diet
lifestyle
nothing
prevent
cure
vtv
therapeutics
vtv
therapeutics
biopharmaceutical
company
focused
developing
oral
small
molecule
drug
candidates
vtv
pipeline
clinical
drug
candidates
led
programs
treatment
type
diabetes
alzheimer
disease
inflammatory
disorders
vtv
development
partners
pursuing
additional
indications
type
diabetes
chronic
obstructive
pulmonary
disease
copd
genetic
mitochondrial
diseases
information
please
visit
follow
us
twitter
vtvtherapeutics
statements
release
contains
statements
involve
risks
uncertainties
statements
identified
use
terminology
including
terms
anticipate
believe
could
estimate
expect
intend
may
plan
potential
predict
project
target
would
case
negative
various
comparable
terminology
statements
statements
historical
facts
contained
release
including
statements
regarding
timing
clinical
trials
strategy
future
operations
future
financial
position
future
revenue
projected
costs
prospects
plans
objectives
management
expected
market
growth
statements
statements
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
important
factors
could
cause
results
vary
expectations
include
described
heading
risk
factors
annual
report
form
filings
sec
statements
reflect
views
respect
future
events
date
release
based
assumptions
subject
risks
uncertainties
given
uncertainties
place
undue
reliance
statements
statements
represent
estimates
assumptions
date
release
except
required
law
undertake
obligation
update
review
publicly
statements
whether
result
new
information
future
events
otherwise
date
release
anticipate
subsequent
events
developments
cause
views
change
statements
reflect
potential
impact
future
acquisitions
merger
dispositions
joint
ventures
investments
may
undertake
qualify
statements
cautionary
statements
contacts
investors
corey
davis
lifesci
advisors
cdavis
media
glenn
silver
lazar
finn
partners
gsilver
